ReviewHaematologica2016
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.
Review in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).Frontiers in immunology · 2026Article
- SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed/Refractory AML.Clinical lymphoma, myeloma & leukemia · 2025Review
- Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC.Frontiers in immunology · 2025Article
- Article
- Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.Haematologica · 2024Article
- The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.Frontiers in immunology · 2024Review
- STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance.Frontiers in immunology · 2024Article
- Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2023Article
- Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.Bone marrow transplantation · 2023Article
- Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case Report.Frontiers in immunology · 2023Article
- Transplant in AML with measurable residual disease: proceed or defer?Hematology. American Society of Hematology. Education Program · 2022Article
- Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.Current oncology reports · 2022Review
- Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology.Current oncology (Toronto, Ont.) · 2022Review
- Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning.Blood advances · 2022Article
- The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Frontiers in oncology · 2022Review
- Disruption of the oral microbiota is associated with a higher risk of relapse after allogeneic hematopoietic stem cell transplantation.Scientific reports · 2021Article
- CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.Nature biomedical engineering · 2021Article
- A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.American journal of blood research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia is a clonal neoplasm derived from myeloid progenitor cells with a varying outcome. The initial goal of treatment is the achievement of complete remission, defined for over 40 years by morphology. However, without additional post-remission treatment the majority of patients relapse. In many cases of acute myeloid leukemia, allogeneic stem cell transplantation offers the best prospects of cure. In 2013, 5608 stem cell transplantations in acute myeloid leukemia were performed in Europe (5228 allogeneic and 380 autologous stem cell transplantations). Most stem cell transplantations are performed in first complete remission. However, despite a considerable reduction in the chance of relapse, in most studies, overall survival benefit of allogeneic stem cell transplantation is modest due to substantial non-relapse mortality. Here we discuss the many factors related to the risk of relapse after allogeneic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.